Direct anti-atherosclerotic therapy; Development of natural anti-atherosclerotic drugs preventing cellular cholesterol retention

Current Pharmaceutical Design

Volumn 19, Issue 33, 2013, Pages 5909-5928

  Orekhov, Alexander N ^a,b  

^a Institute for Atherosclerosis Research   (Russian Federation)

^b INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

Author keywords

Allicor; Anti atherosclerotic therapy; Atherosclerosis; Cell culture; Drugs; Imaging; Natural products

Indexed keywords

ALLICOR; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ASCORBIC ACID; ATENOLOL; ATORVASTATIN; CHLORTALIDONE; CHOLESTEROL; EZETIMIBE; GARLIC EXTRACT; HYDROCHLOROTHIAZIDE; INFLAMINAT; ISRADIPINE; KARINAT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; MEVINOLIN; NICOTINIC ACID; NIFEDIPINE; PINDOLOL; PLACEBO; POMEGRANATE EXTRACT; PRAVASTATIN; PROPRANOLOL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TIMOLOL; UNCLASSIFIED DRUG; VERAPAMIL;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CALENDULA; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG RELEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GARLIC; HUMAN; HYPERTENSION; ISCHEMIA; LIPID STORAGE; MASS SCREENING; NONHUMAN; PLANT LEAF; PLANT SEED; POMEGRANATE JUICE; POSTMENOPAUSE; PRIORITY JOURNAL; REMISSION; REVIEW; TEA; THERAPY;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL PRODUCTS; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; TREATMENT OUTCOME;

EID: 84878759307     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319330011     Document Type: Review

References (144)

1. Martin SS, Blumenthal RS, Miller M. LDL cholesterol: the lower the better. Med Clin North Am 2012; 96: 13-26.
2. Tardif JC, Lesage F, Harel F, Romeo P, Pressacco J. Imaging biomarkers in atherosclerosis trials. Circ Cardiovasc Imaging 2011; 4: 319-33.
3. Verhamme P, Kerkhof F, Buysschaert I, Rietzschel E, de Groot E. Carotid intima-media thickness: more than a research tool? Acta Cardiol 2010; 65: 59-66.
4. Arsenault BJ, Kritikou EA, Tardif JC. Regression of atherosclerosis. Curr Cardiol Rep 2012; 14: 443-9.
5. Simon A, Giral P, Levenson J. Extracoronary atherosclerotic plaque at multiple sites and total coronary calcification deposit in asymptomatic men. Association with coronary risk profile. Circulation 1995; 92: 1414-21.
6. Mitchell JR, Schwartz CJ. Relationship between arterial disease at different sites. Br Med J 1962; 1: 1293-301.
7. Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. Circulation 1990; 82: 1230-42.
8. Geroulakos G, O'Gorman DJ, Kalodiki E, Sheridan DJ, Nicolaides AN. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J 1994; 15: 781-5.
9. Geroulakos G, O'Gorman D, Nicolaides A, Sheridan D, Elkeles R, Shaper AG. Carotid intima-media thickness: correlation with the British Regional Heart Study risk score. J Intern Med 1994; 235: 431-3.
10. Crouse JR 3rd, Craven TE, Hagaman AP, Bond MG. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation 1995; 92: 1141-7.
11. Blankenhorn DH, Hodis HN. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994; 14: 177-92.
12. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262-9.
13. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993; 87: 1156-65.
14. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146: 483-94.
15. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96: 1432-7.
16. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
17. Davignon J. Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects. Am J Cardiol 1998; 81: 17F-24F.
18. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137 Suppl: S101-9.
19. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002; 97: 105-16.
20. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002; 87: 1451-8.
21. Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 2001; 11: 328-43.
22. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9.
23. Gotto Jr AM Jr, Farmer JA. Pleiotropic effects of statins: do they matter? Curr Opin Lipidol 2001; 12: 391-4.
24. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2: 208-17.
25. Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Am J Cardiol 1995; 76: 47C-53C.
26. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16: 697-704.
27. McTavish D, Sorkin EM. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1991; 42: 65-89.
28. Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 76: 54C-59C.
29. Salonen R, Nyssönen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995; 76: 34C-39C.
30. De Groot E, Jukema JW, Montauban van Swijndregt AD, et al. Bmode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998; 31: 1561-7.
31. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
32. Baldassarre D, Veglia F, Gobbi C, et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis 2000; 151: 575-83.
33. Crouse JR 3rd, Raichlen JS, Riley WA, et al. METEOR Study Group. Effect of rosuvastatin on progression of carotid intimamedia thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 1344-53.
34. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357: 577-81.
35. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055-60.
36. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7.
37. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intimamedia thickness: ARBITER 3. Curr Med Res Opin 2006; 22: 2243-50.
38. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361: 2113-22.
39. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-14.
40. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-300.
41. Tardif JC, Grégoire J, L'Allier PL, et al. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297: 1675-82.
42. Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous deliidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010; 55: 2727-35.
43. Catapano AL. Calcium antagonists and atherosclerosis. Experimental evidence. Eur Heart J 1997; 18 Suppl A: A80-6.
44. Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists. State of the art. Am J Med 1989; 86: 27-32.
45. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785-91.
46. Zanchetti A, Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.
47. Simon A, Gariépy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949-54.
48. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-69.
49. Lonn E, Yusuf S, Dzavik V, et al. SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-25.
50. Kruth HS: Receptor-independent fluid-phase pinocytosis mechanisms for induction of foam cell formation with native low-density lipoprotein particles. Curr Opin Lipidol 2011; 22: 386-93.
51. Yuan Y, Li P, Ye J. Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis. Protein Cell 2012; 3: 173-81.
52. Orekhov AN, Tertov VV, Mukhin DN, Mikhailenko IA. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells. Discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem Biophys Res Commun 1989; 162: 206-11.
53. Orekhov AN, Tertov VV, Mukhin DN. Desialylated low density lipoprotein-naturally occurring modified lipoprotein with atherogenic potency. Atherosclerosis 1991; 86: 153-61.
54. Tertov VV, Sobenin IA, Gabbasov ZA, Popov EG, Orekhov AN. Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins. Biochem Biophys Res Commun 1989; 163: 489-94.
55. Tertov VV, Sobenin IA, Tonevitsky AG, Orekhov AN, Smirnov VN. Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography. Biochem Biophys Res Commun 1990; 167: 1122-7.
56. Tertov VV, Sobenin IA, Orekhov AN, Jaakkola O, Solakivi T, Nikkari T. Characteristics of low density lipoprotein isolated from circulating immune complexes. Atherosclerosis 1996; 122: 191-9.
57. Tertov VV, Kaplun VV, Sobenin IA, Boytsova EY, Bovin NV, Orekhov AN. Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis 2001; 159: 103-15.
58. Avogaro P, Bon GB, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis 1988; 8: 79-87.
59. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23: 97-104.
60. Tertov VV, Bittolo-Bon G, Sobenin IA, Cazzolato G, Orekhov AN, Avogaro P. Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions. Exp Mol Pathol 1995; 62: 166-72.
61. Tertov VV, Sobenin IA, Orekhov AN. Similarity between naturally occurring modified desialylated, electronegative and aortic low density lipoprotein. Free Radic Res 1996; 25: 313-9.
62. La Belle M, Krauss RM. Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass patterns. J Lipid Res 1990; 31: 1577-88.
63. Kirk JK, Davis SW, Hildebrandt CA, Strachan EN, Peechara ML, Lord R. Characteristics associated with glycemic control among family medicine patients with type 2 diabetes. N C Med J 2011; 72: 345-50.
64. Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 2011; 22: 254-61.
65. Jiang X, Yang Z, Chandrakala AN, Pressley D, Parthasarathy S. Oxidized low density lipoproteins--do we know enough about them? Cardiovasc Drugs Ther 2011; 25: 367-77.
66. Orekhov AN, Tertov VV, Kabakov AE, Adamova IYu, Pokrovsky SN, Smirnov VN. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb 1991; 11: 316-26.
67. Orekhov AN, Tertov VV. Atherogenicity of autoantibodies against low density lipoprotein. Agents Actions 1991; 32: 128-9.
68. Lopes-Virella MF, Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol 2010; 134: 55-65.
69. Tertov VV, Orekhov AN, Sayadyan KhS, et al. Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis 1990; 81: 183-9.
70. Kacharava AG, Tertov VV, Orekhov AN. Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Ann Med 1993; 25: 551-5.
71. Tertov VV, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, Smirnov VN. Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Pathol 1990; 52: 300-8.
72. Orekhov AN, Kalenich OS, Tertov VV, Novikov ID. Lipoprotein immune complexes as markers of atherosclerosis. Int J Tissue React 1991; 13: 233-6.
73. Orekhov AN, Kalenich OS, Tertov VV, et al. Diagnostic value of immune cholesterol as a marker for atherosclerosis. J Cardiovasc Risk 1995; 2: 459-66.
74. Sobenin IA, Karagodin VP, Melnichenko AC, Bobryshev YV, Orekhov AN. Diagnostic and Prognostic Value of Low Density Lipoprotein-Containing Circulating Immune Complexes in Atherosclerosis. J Clin Immunol 2012 Oct 17. [Epub ahead of print]
75. Sobenin IA, Orekhova VA, Melnichenko A, Bobryshev YV, Orekhov AN. Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. Int J Cardiol 2012 Oct 13. [Epub ahead of print]
76. Orekhov AN, Tertov VV, Mukhin DN, et al. Insolubilization of low density lipoprotein induces cholesterol accumulation in cultured subendothelial cells of human aorta. Atherosclerosis 1989; 79: 59-70.
77. Glukhova MA, Kabakov AE, Frid MG, et al. Modulation of human aorta smooth muscle cell phenotype: a study of muscle-specific variants of vinculin, caldesmon, and actin expression. Proc Natl Acad Sci USA 1988; 85: 9542-6.
78. Orekhov AN, Tertov VV, Mukhin DN, et al. Association of lowdensity lipoprotein with particulate connective tissue matrix components enhances cholesterol accumulation in cultured subendothelial cells of human aorta. Biochim Biophys Acta 1987; 928: 251-8.
79. Melnichenko AA, Aksenov DV, Myasoedova VA, et al. Pluronic block copolymers inhibit low density lipoprotein self-association. Lipids 2012; 47: 995-1000.
80. Tertov VV, Orekhov AN, Sobenin IA, et al. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circ Res 1992; 71: 218-28.
81. Aksenov DV, Medvedeva LA, Skalbe TA, et al. Deglycosylation of apo B-containing lipoproteins increase their ability to aggregate and to promote intracellular cholesterol accumulation in vitro. Arch Physiol Biochem 2008; 114: 349-56.
82. Rekhter MD, Andreeva ER, Mironov AA, Orekhov AN. Threedimensional cytoarchitecture of normal and atherosclerotic intima of human aorta. Am J Pathol 1991; 138: 569-80.
83. Orekhov AN, Andreeva ER, Krushinsky AV, Smirnov VN. Primary cultures of enzyme-isolated cells from normal and atherosclerotic human aorta. Med Biol 1984; 62: 255-9.
84. Orekhov AN, Tertov VV, Novikov ID, et al. Lipids in cells of atherosclerotic and uninvolved human aorta. I. Lipid composition of aortic tissue and enzyme isolated and cultured cells. Exp Mol Pathol 1985; 42: 117-37.
85. Orekhov AN, Krushinsky AV, Andreeva ER, Repin VS, Smirnov VN. Adult human aortic cells in primary culture: heterogeneity in shape. Heart Vessels 1986; 2: 193-201.
86. Yamada S, Guo X, Yoshizawa M, et al. Primary desmoplastic cutaneous leiomyosarcoma associated with high MIB-1 labeling index: a teaching case giving rise to diagnostic difficulties on a small biopsy specimen. Pathol Res Pract 2011; 207: 728-32.
87. Orekhov AN, Kosykh VA, Repin VS, Smirnov VN. Cell proliferation in normal and atherosclerotic human aorta. II. Autoradiographic observation on deoxyribonucleic acid synthesis in primary cell culture. Lab Invest 1983; 48: 749-54.
88. Orekhov AN, Tertov VV, Kudryashov SA, Khashimov KhA, Smirnov VN. Primary culture of human aortic intima cells as a model for testing anti-atherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipidlowering agents. Atherosclerosis 1986; 60: 101-10.
89. Orekhov AN, Tertov VV, Kudryashov SA, Smirnov VN. Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells. Circ Res 1990; 66: 311-20.
90. Tertov VV, Orekhov AN, Repin VS, Smirnov VN. Dibutyryl cyclic AMP decrease proliferative activity and the cholesteryl ester content in cultured cells of atherosclerotic human aorta. Biochem Biophys Res Commun 1982; 109: 1228-33.
91. Tertov VV, Orekhov AN, Smirnov VN. Effect of cyclic AMP on lipid accumulation and metabolism in human atherosclerotic aortic cells. Atherosclerosis 1986; 62: 55-64.
92. Tertov VV, Orekhov AN, Smirnov VN. Agents that increase cellular cyclic AMP inhibit proliferative activity and decrease lipid content in cells cultured from atherosclerotic human aorta. Artery 1986; 13: 365-72.
93. Tertov VV, Orekhov AN, Kudryashov SA, et al. Cyclic nucleotides and atherosclerosis: studies in primary culture of human aortic cells. Exp Mol Pathol 1987; 47: 377-89.
94. Kudryashov SA, Tertov VV, Orekhov AN, Geling NG, Smirnov VN. Regression of atherosclerotic manifestations in primary culture of human aortic cells: effects of prostaglandins. Biomed Biochim Acta 1984; 43: S284-6.
95. Orekhov AN, Tertov VV, Smirnov VN. Prostacyclin analogues as anti-atherosclerotic drugs. Lancet 1983; 2: 521.
96. Orekhov AN, Tertov VV, Mazurov AV, Andreeva ER, Repin VS, Smirnov VN. "Regression" of atherosclerosis in cell culture: effects of stable prostacyclin analogues. Drug Devel Res 1986; 9: 189-201.
97. Baldenkov GN, Akopov SE, Li HR, Orekhov AN. Prostacyclin, thromboxane A2 and calcium antagonists: effects on atherosclerotic characteristics of vascular cells. Biomed Biochim Acta 1988; 47: S324-7.
98. 2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta. The effect of calcium antagonists. Atherosclerosis 1988; 72: 245-8.
99. Tertov VV, Panosyan AG, Akopov SE, Orekhov AN. The effects of eicozanoids and lipoxygenase inhibitors on the lipid metabolism of aortic cells. Biomed Biochim Acta 1988; 47: S286-8.
100. Orekhov AN, Misharin AYu, Tertov VV, et al. Artificial HDL as an anti-atherosclerotic drug. Lancet 1984; 2: 1149-50.
101. Orekhov AN, Tertov VV, Khashimov KhA, Kudryashov SA, Smirnov VN. Antiatherosclerotic effects of verapamil in primary culture of human aortic intimal cells. J Hypertension 1986; 4: S153-5.
102. Orekhov AN, Tertov VV, Khashimov KhA, Kudryashov SA, Smirnov VN. Evidence of anti-atherosclerotic action of verapamil from direct effects on arterial cells. Am J Cardiol 1987; 59: 495-6.
103. Orekhov AN, Baldenkov GN, Tertov VV, et al. Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, betablockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol 1988; 12: S66-8.
104. Orekhov AN, Baldenkov GN, Tertov VV, et al. Antiatherosclerotic effects of calcium antagonists. Study in human aortic cell culture. Herz 1990; 15: 139-45.
105. Giessler Ch, Fahr A, Tertov VV, et al. Trapidil derivatives as potential anti-atherosclerotic drugs. Arzneimittelforschung 1987; 37-I: 538-41.
106. Heinroth-Hoffmann I, Kruger J, Tertov VV, Orekhov AN, Mest HJ. Influence of trapidil and trapidil derivatives on the content of cyclic nucleotides in human intima cells cultured from atherosclerotic plaques. Drug Devel Res 1990; 19: 321-7.
107. Li HR, Tertov VV, Vasil'ev AV, Tutel'yan VA, Orekhov AN. Antiatherogenic and anti-atherosclerotic effects of mushroom extracts revealed in human aortic intima cell culture. Drug Devel Res 1989; 17: 109-17.
108. Orekhov AN, Ruda MYa, Baldenkov GN, et al. Atherogenic effects of beta blockers on cells cultured from normal and atherosclerotic aorta. Am J Cardiol 1988; 61: 1116-7.
109. Chazov EI, Tertov VV, Orekhov AN, et al. Atherogenicity of blood serum from patients with coronary heart disease. Lancet 1986; 2: 595-8.
110. Tertov VV, Orekhov AN, Li Hwa Ryong, Smirnov VN. Intracellular cholesterol accumulation is accompanied by enhanced prolifera tive activity of human aortic intimal cells. Tissue Cell 1988; 20: 849-54.
111. Orekhov AN, Tertov VV, Pokrovsky SN, et al. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res 1988; 62: 421-9.
112. Tertov VV, Orekhov AN, Martsenyuk ON, Perova NV, Smirnov VN. Low density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Exp Mol Pathol 1989; 50: 337-47.
113. Orekhov AN. In vitro models of anti-atherosclerotic effects of cardiovascular drugs. Am J Cardiol 1990; 66: 23I-28I.
114. Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis 2009; 52: 46-60.
115. Schulman IH, Zachariah M, Raij L. Calcium channel blockers, endothelial dysfunction, and combination therapy. Aging Clin Exp Res 2005; 17 Suppl 4: 40-5.
116. Loaldi A, Polese A, Montorsi P, De Cesare N, Fabbiocchi F, Ravagnani P, Guazzi MD. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol 1989; 64: 433-9.
117. Fei W, Tong T, Yifeng P, Jingli T, et al. A modified rabbit model of carotid atherosclerotic plaque suitable for the stroke study and MRI evaluation. Int J Neurosci 2011; 121: 662-9.
118. Orekhov AN, Grünwald J. Effects of garlic on atherosclerosis. Nutrition 1997; 13: 656-63.
119. Orekhov AN, Sobenin IA, Korneev NV, et al. Anti-Atherosclerotic Therapy Based on Botanicals. Recent Pat Cardiovasc Drug Discov 2013; 8: 000-000.
120. Koscielny J, Klüssendorf D, Latza R, et al. The antiatherosclerotic effect of Allium sativum. Atherosclerosis 1999; 144: 237-49.
121. Crouse JR 3rd, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75: 455-9.
122. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64.
123. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-10.
124. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two-and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993; 88: 20-8.
125. Hodis HN. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study. J Cardiovasc Pharmacol 1995; 25 Suppl 4: S25-31.
126. Blankenhorn DH, Azen SP, Kramsch DM, et al. MARS Research Group. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993; 119: 969-76.
127. Lavu M, Bhushan S, Lefer DJ. Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential. Clin Sci (Lond) 2011; 120: 219-29.
128. Prasad K. Natural products in regression and slowing of progression of atherosclerosis. Curr Pharm Biotechnol 2010; 11: 794-800.
129. El-Sayyad HI, Abou-El-Naga AM, Gadallah AA, Bakr IH. Protective effects of Allium sativum against defects of hypercholesterolemia on pregnant rats and their offspring. Int J Clin Exp Med 2010; 3: 152-163
130. Lei YP, Liu CT, Sheen LY, Chen HW, Lii CK. Diallyl disulfide and diallyl trisulfide protect endothelial nitric oxide synthase against damage by oxidized low-density lipoprotein. Mol Nutr Food Res 2010; 54 Suppl 1: S42-52.
131. Reinhart KM, Talati R, White CM, Coleman CI. The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Res Rev 2009; 22: 39-48.
132. Chen ZY, Jiao R, Ma KY. Cholesterol-lowering nutraceuticals and functional foods. J Agric Food Chem 2008; 56: 8761-73.
133. Vidyashankar S, Sambaiah K, Srinivasan K. Regression of preestablished cholesterol gallstones by dietary garlic and onion in experimental mice. Metabolism 2010; 59: 1402-12.
134. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83: 456S-0S.
135. Aidinian G, Weiswasser JM, Arora S. Carotid plaque morphologic characteristics. Persp Vasc Surg Endovasc Ther 2006; 18: 63-70.
136. Daugherty A, Webb NR, Rateri DL, King VL. The immune system and atherogenesis. Cytokine regulation of macrophage functions in Atherogenesis. J Lipid Res 2005; 46: 1812-22.
137. Burger HG, Maclennan AH, Huang KE, Castelo-Branco C. Evidence-based assessment of the impact of the WHI on women's health. Climacteric 2012; 15: 281-7.
138. de Villiers TJ, Stevenson JC. The WHI: the effect of hormone replacement therapy on fracture prevention. Climacteric 2012; 15: 263-6.
139. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol 2011; 29: 2342-9.
140. Smith NL, Wiley JR, Legault C, et al. Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Menopause 2008; 15: 1145-50.
141. Masood DE, Roach EC, Beauregard KG, Khalil RA. Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease. Curr Drug Metab 2010; 11: 693-714.
142. Pellegrini CN, Vittinghoff E, Lin F, Hulley SB, Marcus GM. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart 2009; 95: 704-8.
143. Davidson MH, Maki KC, Dicklin MR, et al. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol 2009; 104: 936-42.
144. Slevin M, Ahmed N, Wang Q, McDowell G, Badimon L. Unique vascular protective properties of natural products: supplements or future main-line drugs with significant anti-atherosclerotic potential? Vasc Cell 2012; 4: 9.